SRSF2 P95L

CI-VAR-00003430Explore in graph →NP_001182356.1:p.Pro95LeuNM_001195427.2:c.284C>TClinVar 2504111 CIViC 4303 rs751713049

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Myelodysplastic Syndrome1
SRSF2 P95L	(oncogenic)	Oncogenic	B	Supports Oncogenicity	5	submitted	EID12483 The SRSF2 P95L mutation, located in the RNA recognition motif domain, is a statistically significant hotspot in myeloid malignancies. In vitro studies using HeLa and K562 cells show that P95L disrupts… (full text at CIViC) PMID 26124281 · Komeno et al., 2015 · Open in CIViC	civic
Myeloid Neoplasm1
SRSF2 P95L	CTX-712	Predictive	D	Supports Sensitivity Response	3	accepted	EID11027 Several splicing factors known to drive myeloid neoplasms (including SRSF2) require phosphorylation by CLK family kinases for nuclear translocation. The authors describe development of an inhibiter o… (full text at CIViC) Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
2504111	Pathogenic	no assertion criteria provided	0	Atypical chronic myeloid leukemia, BCR-ABL1 negative; Acute myeloid leukemia	somatic	2	Jun 08, 2023	clinvar